COMPARE · Data as of August 21, 2026
AZN vs PAHC
Verdict: Side-by-side breakdown using the Bull Rankings model. AZN scored 74.5, PAHC scored 72.1 — AZN leads.
Compare another set
AZN
AstraZeneca PLC
74.5
$165.98 · $257.4B
fundamentals as of
Score gap
2.4
AZN leads
PAHC
Phibro Animal Health Corp
72.1
$36.32 · $1.5B
At a glance · who leads each dimension, on the model's own rules
- CheapestPAHC14.5x
- Fastest growthPAHC+26.0%
- Strongest balance sheetAZN0.64
- Highest qualityAZN78 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
AZN
stronger →← stronger
PAHC
78
Qualityreturns · margins · balance sheet
61
78
Growthrevenue & earnings expansion
86
68
Valuevaluation vs sector peers
71
PAHC is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AZN
PAHC
$11.8bA-
FCF
$13mC-
+8.6%B
Rev
+26.0%A-
0.64C+
D/E
2.52D+
24.9xB
P/E
14.5xB+
1.42B
PEG
—
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AZN
PAHC
19% above
Price vs fair valuelower is cheaper
391% above
~13%/yr
Growth the price implies10-yr FCF · lower = less priced in
~59%/yr
-26%
1-yr DCF upside
-85%
-16%
5-yr DCF upside
-80%
+1%
10-yr DCF upside
-70%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AZN
Why this score
- Raising its dividend
PAHC
No notable signals flagged.
The companies
AZNAstraZeneca PLC
Why now
Drug Manufacturers - General · market cap $257.4b. Down 22% from 52-week high of $212.71 — deep drawdown territory. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $213.99 (implying +29% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
PAHCPhibro Animal Health Corp
Why now
Pharmaceuticals · market cap $1.5b. Down 40% from 52-week high of $60.08 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory.
Moat
ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.52 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 40% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AZN and PAHC diverge
On the headline score the gap is 2.4 points in favor of AZN. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityAZN 78.2 · PAHC 61.3AZN +16.9
- GrowthAZN 78.5 · PAHC 85.6PAHC +7.1
- ValueAZN 67.5 · PAHC 71.4PAHC +3.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.